Rezolute

Rezolute Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism

We're heading to New Orleans this weekend for the Neuroendocrine Cancer Awareness Network's NET Patient Conference! This...
06/05/2026

We're heading to New Orleans this weekend for the Neuroendocrine Cancer Awareness Network's NET Patient Conference! This is a great opportunity to learn from leading experts, explore the latest in neuroendocrine tumor (NET) care, and connect with an incredible community of patients, caregivers, and HCPs.

Learn more: https://bit.ly/4uUshug

Mark your calendar: Global Hyperinsulinism Awareness Day is this Sunday, June 7!On this day, we celebrate the incredible...
06/05/2026

Mark your calendar: Global Hyperinsulinism Awareness Day is this Sunday, June 7!

On this day, we celebrate the incredible advocacy organizations around the world—including Congenital Hyperinsulinism International, The Children's Hyperinsulinism Charity, Kongenitaler Hyperinsulinismus e.V., HiperinsulinismoCongénito.ORG, and many others. Thank you for your unwavering commitment to improving the lives of individuals and families affected by . Your partnership and perseverance inspire us every day.

We’re pleased to announce four presentations at the Annual Meeting of the Endocrine Society (ENDO) being held in Chicago...
06/04/2026

We’re pleased to announce four presentations at the Annual Meeting of the Endocrine Society (ENDO) being held in Chicago, IL later this month.

Our presentations will include one oral presentation on previously reported results from the Phase 3 sunRIZE study in congenital HI, which will be made by Huseyin Demirbilek, M.D., Professor, Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Principal Investigator of the sunRIZE study. Additionally, three poster presentations will cover the natural history and adverse outcomes associated with congenital HI, as well as a case series report on compassionate use of ersodetug in a cohort of patients with tumor HI.

Learn more: https://bit.ly/4uSZ1Eb

We’re looking forward to attending the Jefferies Global Healthcare Conference this week, where our leadership team will ...
06/03/2026

We’re looking forward to attending the Jefferies Global Healthcare Conference this week, where our leadership team will discuss the transformative potential of ersodetug for patients with .

Watch our fireside chat on Thursday, June 4 at 3:45 PM EDT here: https://bit.ly/43QgYqM

Today we announced positive interim data from our Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (HI). The s...
06/02/2026

Today we announced positive interim data from our Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (HI). The study is now 50% enrolled, and 6 of 8 participants have already met the responder criterion for the study’s primary endpoint.

We are excited by these interim observations as they largely mirror what we previously observed and reported from an initial case series of patients from our expanded access program (EAP) for compassionate use.

We remain grateful to the patients, caregivers, and investigator partners who support this ongoing program, and we look forward to reporting topline results for the fully enrolled study, expected in the second half of 2026.

Learn more: https://bit.ly/43dUlfQ

"Together for Parents" — this year's theme — reminds us that no family should face alone.For families managing conge...
06/01/2026

"Together for Parents" — this year's theme — reminds us that no family should face alone.

For families managing congenital , parenting means navigating uncertainty through complex healthcare journeys. They need support, connection, and resources.

At Rezolute, we're inspired by the strength of this community and are committed to advancing research and therapies that help families gain greater control over their lives.

Thank you UNICEF for highlighting the realities of caregiving. Learn more about the Global Day of Parents: https://bit.ly/4wYOmZW

Stories from families living with drive us forward. We’re inspired by their courage, and we’re dedicated to developing...
05/29/2026

Stories from families living with drive us forward. We’re inspired by their courage, and we’re dedicated to developing treatment options that will give them greater control over their lives.

Congenital hyperinsulinism (cHI) is the most common cause of recurrent and persistent in children. It can lead to progressive and irreversible damage over time, including serious and devastating neurological damage, seizures, neuro-developmental problems, feeding difficulties, and a profound impact on the quality of life for the patient and their family.

We’re working toward creating a different world - one where patients and caregivers no longer live in fear of unpredictable hypoglycemic lows.

Learn more: https://bit.ly/3OmZq0Z

Today we celebrate , a time to honor the families and professionals who drive critical research forward. ❤️ Thank you t...
05/20/2026

Today we celebrate , a time to honor the families and professionals who drive critical research forward.

❤️ Thank you to all the study participants who make medical advancement possible

❤️ Thank you to the clinical research professionals who ensure trials move forward safely and effectively

❤️ Thank you to the clinicians who guide participants through their treatment journey and advocate for better options

Learn more about our clinical trials here: https://bit.ly/42LzGj6

We're excited to participate in the H.C. Wainwright Investor Conference in New York this week.If you’re attending, we ...
05/18/2026

We're excited to participate in the H.C. Wainwright Investor Conference in New York this week.

If you’re attending, we look forward to connecting to share updates on the exciting milestones ahead for our two late-stage programs.

Navigating (HI) comes with challenges no one should face alone—that’s why we’re here to support and stay connected. Be...
05/14/2026

Navigating (HI) comes with challenges no one should face alone—that’s why we’re here to support and stay connected. Be sure to sign up for 𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 and look out for our May edition.

𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘙𝘦𝘱𝘰𝘳𝘵 brings awareness, resources, and support to those impacted by frequent and severe hypoglycemia related to HI.

Subscribe here: https://bit.ly/4iadvda

Address

275 Shoreline Drive, Ste. 500
Redwood City, CA
94065

Telephone

+16502064507

Website

Alerts

Be the first to know and let us send you an email when Rezolute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Rezolute:

Shortcuts

Share

Category